Medifast Reports Q3 2026 Results and Strategic Pivot Toward Metabolic Health
Medifast (MED) reported third-quarter revenue of $72 million, highlighting a strategic shift toward metabolic health to compete with the rising popularity of GLP-1 medications. While the number of active earning coaches decreased significantly from 19.5 thousand to 10.2 thousand year-over-year, management successfully increased average revenue per coach by 54.1% through a simplified commission structure designed to reward high productivity. The company is also executing 'Project Catalyst,' a cost-realignment initiative involving facility closures and workforce reductions to protect gross margins. With $172.5 million in cash and no debt, Medifast aims to leverage AI and its new Trilogy brand—which focuses on muscle preservation during weight loss—to return to growth. Management remains committed to achieving profitability by the fourth quarter of 2026.
Tickers: $MED
Topics: cost reduction earnings call revenue strategic pivot
Read the full article at Motley Fool
Part of the story DeFi Technologies Schedules Shareholder Call for Q3 2026 Financial Results (51 articles)